BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 2547935)

  • 1. Serotonergic involvement in the antinociceptive action of and the development of tolerance to the kappa-opioid receptor agonist, U-50, 488H.
    Ho BY; Takemori AE
    J Pharmacol Exp Ther; 1989 Aug; 250(2):508-14. PubMed ID: 2547935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of chronic administration of U-50,488H on tolerance to its pharmacological actions and on multiple opioid receptors in rat brain regions and spinal cord.
    Bhargava HN; Gulati A; Ramarao P
    J Pharmacol Exp Ther; 1989 Oct; 251(1):21-6. PubMed ID: 2552075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Release by U-50,488H of [3H]serotonin from brain slices and spinal cord synaptosomes of U-50,488H-tolerant and nontolerant mice.
    Ho BY; Takemori AE
    J Pharmacol Exp Ther; 1990 Jul; 254(1):8-12. PubMed ID: 2164102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kappa opioid analgesia is dependent on serotonergic mechanisms.
    Vonvoigtlander PF; Lewis RA; Neff GL
    J Pharmacol Exp Ther; 1984 Nov; 231(2):270-4. PubMed ID: 6092612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mu antagonist properties of kappa agonists in a model of rat urinary bladder motility in vivo.
    Sheldon RJ; Nunan L; Porreca F
    J Pharmacol Exp Ther; 1987 Oct; 243(1):234-40. PubMed ID: 2822899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional interaction among opioid receptor types: up-regulation of mu- and delta-opioid receptor functions after repeated stimulation of kappa-opioid receptors.
    Khotib J; Narita M; Suzuki M; Yajima Y; Suzuki T
    Neuropharmacology; 2004 Mar; 46(4):531-40. PubMed ID: 14975677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antinociceptive actions of dexmedetomidine and the kappa-opioid agonist U-50,488H against noxious thermal, mechanical and inflammatory stimuli.
    Idänpään-Heikkilä JJ; Kalso EA; Seppälä T
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1306-13. PubMed ID: 7996439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roles of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse.
    Porreca F; Mosberg HI; Hurst R; Hruby VJ; Burks TF
    J Pharmacol Exp Ther; 1984 Aug; 230(2):341-8. PubMed ID: 6086883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-dependent antagonism and potentiation of nitrous oxide antinociception by naloxone in mice.
    Quock RM; Curtis BA; Reynolds BJ; Mueller JL
    J Pharmacol Exp Ther; 1993 Oct; 267(1):117-22. PubMed ID: 8229738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of morphine in rats treated chronically with U-50,488 H, a kappa opioid receptor agonist.
    Bhargava HN; Ramarao P; Gulati A
    Eur J Pharmacol; 1989 Mar; 162(2):257-64. PubMed ID: 2542058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kappa agonists inhibit gastric emptying but not acid secretion in rhesus monkeys.
    Touzeau PL; Shea-Donohue T
    J Pharmacol Exp Ther; 1990 Jun; 253(3):1010-6. PubMed ID: 1972746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modification of the binding of [3H]MK-801 to brain regions and spinal cord of rats treated chronically with U-50,488H, a kappa-opioid receptor agonist.
    Bhargava HN; Kumar S
    Brain Res; 1997 Feb; 749(2):347-50. PubMed ID: 9138737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of repeated administration of U-50,488H, a kappa opioid receptor agonist, on central 5-HT1 and 5-HT2 receptors in the rat.
    Gulati A; Ramarao P; Bhargava HN
    Pharmacology; 1989; 39(3):145-53. PubMed ID: 2587620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist.
    Vonvoigtlander PF; Lahti RA; Ludens JH
    J Pharmacol Exp Ther; 1983 Jan; 224(1):7-12. PubMed ID: 6129321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. beta-Endorphin-like immunoreactivity in discrete brain regions, spinal cord, pituitary gland and peripheral tissues of U-50,488H-tolerant and -abstinent rats.
    Bhargava HN; Matwyshyn GA; Rattan AK; Koo KL; Tejwani GA
    J Pharmacol Exp Ther; 1994 Feb; 268(2):856-61. PubMed ID: 8113998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of serotonergic mechanisms in the inhibitory effect of U-50,488H on glutamate-induced lethality in mice.
    Kamei J; Igarashi H; Kasuya Y
    Res Commun Chem Pathol Pharmacol; 1992 Mar; 75(3):357-60. PubMed ID: 1509202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-tolerance between mu- and kappa-opioid agonists in the guinea pig ileum myenteric plexus.
    Garaulet JV; Laorden ML; Milanés MV
    J Pharmacol Exp Ther; 1994 Jun; 269(3):993-9. PubMed ID: 8014886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of spinal kappa opioid receptors in the blockade of the development of antinociceptive tolerance to morphine.
    Takahashi M; Senda T; Kaneto H
    Eur J Pharmacol; 1991 Aug; 200(2-3):293-7. PubMed ID: 1664330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-tolerance between kappa and mu opioid agonists in the guinea pig ileum myenteric plexus.
    Garaulet JV; Milanés MV; Laorden ML
    J Pharmacol Exp Ther; 1995 Feb; 272(2):658-62. PubMed ID: 7853179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological characterization of nalorphine, a kappa 3 analgesic.
    Paul D; Pick CG; Tive LA; Pasternak GW
    J Pharmacol Exp Ther; 1991 Apr; 257(1):1-7. PubMed ID: 1850462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.